Recombinant Mouse gp130 Protein (HEK293), C-His

gp130

Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family[1]. gp130 inhibits the cell growth and migration[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity[4][5]. gp130/IL6ST Protein, Mouse (617a.a, HEK293, His) is a recombinant protein with a His label and is produced by HEK293 cells.

SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

1.Measured by its ability to inhibit the IL-6Rα enhancement of IL-6 activity on M1 mouse myeloid leukemia cells and the ED50 is typically 0.6-3 μg/mL in the presence of 50 ng/mL human IL-6sR and 100 ng/mL human IL-6. 2.Measured by its ability to bind mouse IL-11Ra in a functional ELISA. 3.Immobilized Human gp130 at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately ≤8 ng/mL. 4.Measured by its ability to inhibit IL-6-dependent proliferation of TF-1 cells. The ED50 this effect is 0.1185 ng/mL in the presence of 4 μg/mL Recombinant Human IL-6 R alpha , corresponding to a specific activity is 8.44×10^6 units/mg. Measured by its ability to inhibit IL-6-dependent proliferation of TF-1 cells. The ED50 this effect is 0.1185 ng/mL in the presence of 4 μg/mL Recombinant Human IL-6 R alpha, corresponding to a specific activity is 8.44×106 units/mg.

Interleukin-6 receptor subunit beta; IL-6R-beta; IL-6RB; gp130; CD130

Mouse

HEK293

C-His

Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.

Q00560

Q23-E617

QLLEPCGYIYPEFPVVQRGSNFTAICVLKEACLQHYYVNASYIVWKTNHAAVPREQVTVINRTTSSVTFTDVVLPSVQLTCNILSFGQIEQNVYGVTMLSGFPPDKPTNLTCIVNEGKNMLCQWDPGRETYLETNYTLKSEWATEKFPDCQSKHGTSCMVSYMPTYYVNIEVWVEAENALGKVSSESINFDPVDKVKPTPPYNLSVTNSEELSSILKLSWVSSGLGGLLDLKSDIQYRTKDASTWIQVPLEDTMSPRTSFTVQDLKPFTEYVFRIRSIKDSGKGYWSDWSEEASGTTYEDRPSRPPSFWYKTNPSHGQEYRSVRLIWKALPLSEANGKILDYEVILTQSKSVSQTYTVTGTELTVNLTNDRYVASLAARNKVGKSAAAVLTIPSPHVTAAYSVVNLKAFPKDNLLWVEWTPPPKPVSKYILEWCVLSENAPCVEDWQQEDATVNRTHLRGRLLESKCYQITVTPVFATGPGGSESLKAYLKQAAPARGPTVRTKKVGKNEAVLAWDQIPVDDQNGFIRNYSISYRTSVGKEMVVHVDSSHTEYTLSSLSSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEIE

Extracellular Domain

80-90 kDa.

< 1.0 EU per μg protein as determined by the LAL method.

Freeze-dried powder

PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.